Evans, M., Kozlovski, P., Paldánius, P. M., Foley, J. E., Bhosekar, V., Serban, C., & Avogaro, A. (2017). Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Ther.

Evans, Marc, Plamen Kozlovski, Päivi M. Paldánius, James E. Foley, Vaishali Bhosekar, Carmen Serban, et Angelo Avogaro. "Factors That May Account for Cardiovascular Risk Reduction With a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients With Type 2 Diabetes Mellitus." Diabetes Ther 2017.

Evans, Marc, et al. "Factors That May Account for Cardiovascular Risk Reduction With a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients With Type 2 Diabetes Mellitus." Diabetes Ther 2017.